218 related articles for article (PubMed ID: 31735362)
1. Baseline tumor size and survival outcomes in lung cancer patients treated with immune checkpoint inhibitors.
Hopkins AM; Kichenadasse G; McKinnon RA; Rowland A; Sorich MJ
Semin Oncol; 2019; 46(4-5):380-384. PubMed ID: 31735362
[TBL] [Abstract][Full Text] [Related]
2. Early tumor shrinkage identifies long-term disease control and survival in patients with lung cancer treated with atezolizumab.
Hopkins AM; Kichenadasse G; Karapetis CS; Rowland A; Sorich MJ
J Immunother Cancer; 2020 Jun; 8(1):. PubMed ID: 32503948
[TBL] [Abstract][Full Text] [Related]
3. Development and Validation of a Prognostic Model for Patients with Advanced Lung Cancer Treated with the Immune Checkpoint Inhibitor Atezolizumab.
Hopkins AM; Kichenadasse G; Garrett-Mayer E; Karapetis CS; Rowland A; Sorich MJ
Clin Cancer Res; 2020 Jul; 26(13):3280-3286. PubMed ID: 32086341
[TBL] [Abstract][Full Text] [Related]
4. Baseline Tumor Size as a Predictive and Prognostic Factor of Immune Checkpoint Inhibitor Therapy for Non-small Cell Lung Cancer.
Katsurada M; Nagano T; Tachihara M; Kiriu T; Furukawa K; Koyama K; Otoshi T; Sekiya R; Hazama D; Tamura D; Nakata K; Katsurada N; Yamamoto M; Kobayashi K; Nishimura Y
Anticancer Res; 2019 Feb; 39(2):815-825. PubMed ID: 30711962
[TBL] [Abstract][Full Text] [Related]
5. Patient-reported outcomes as a prognostic marker of survival in patients with advanced nonsmall cell lung cancer treated with immunotherapy.
Hopkins AM; Wagner J; Kichenadasse G; Modi N; Rowland A; Sorich MJ
Int J Cancer; 2020 Dec; 147(11):3085-3089. PubMed ID: 32492185
[TBL] [Abstract][Full Text] [Related]
6. A Model of Overall Survival Predicts Treatment Outcomes with Atezolizumab versus Chemotherapy in Non-Small Cell Lung Cancer Based on Early Tumor Kinetics.
Claret L; Jin JY; Ferté C; Winter H; Girish S; Stroh M; He P; Ballinger M; Sandler A; Joshi A; Rittmeyer A; Gandara D; Soria JC; Bruno R
Clin Cancer Res; 2018 Jul; 24(14):3292-3298. PubMed ID: 29685883
[No Abstract] [Full Text] [Related]
7. Modeled Prognostic Subgroups for Survival and Treatment Outcomes in BRAF V600-Mutated Metastatic Melanoma: Pooled Analysis of 4 Randomized Clinical Trials.
Hauschild A; Larkin J; Ribas A; Dréno B; Flaherty KT; Ascierto PA; Lewis KD; McKenna E; Zhu Q; Mun Y; McArthur GA
JAMA Oncol; 2018 Oct; 4(10):1382-1388. PubMed ID: 30073321
[TBL] [Abstract][Full Text] [Related]
8. Association of Performance Status With Survival in Patients With Advanced Non-Small Cell Lung Cancer Treated With Pembrolizumab Monotherapy.
Sehgal K; Gill RR; Widick P; Bindal P; McDonald DC; Shea M; Rangachari D; Costa DB
JAMA Netw Open; 2021 Feb; 4(2):e2037120. PubMed ID: 33570575
[TBL] [Abstract][Full Text] [Related]
9. Association Between Body Mass Index and Overall Survival With Immune Checkpoint Inhibitor Therapy for Advanced Non-Small Cell Lung Cancer.
Kichenadasse G; Miners JO; Mangoni AA; Rowland A; Hopkins AM; Sorich MJ
JAMA Oncol; 2020 Apr; 6(4):512-518. PubMed ID: 31876896
[TBL] [Abstract][Full Text] [Related]
10. The efficacy of immune checkpoint inhibitors in advanced non-small-cell lung cancer with liver metastases.
Kitadai R; Okuma Y; Hakozaki T; Hosomi Y
J Cancer Res Clin Oncol; 2020 Mar; 146(3):777-785. PubMed ID: 31828427
[TBL] [Abstract][Full Text] [Related]
11. Pretreatment prognostic nutritional index as a novel biomarker in non-small cell lung cancer patients treated with immune checkpoint inhibitors.
Shoji F; Takeoka H; Kozuma Y; Toyokawa G; Yamazaki K; Ichiki M; Takeo S
Lung Cancer; 2019 Oct; 136():45-51. PubMed ID: 31437663
[TBL] [Abstract][Full Text] [Related]
12. Comparisons between tumor burden and other prognostic factors that influence survival of patients with non-small cell lung cancer treated with immune checkpoint inhibitors.
Sakata Y; Kawamura K; Ichikado K; Shingu N; Yasuda Y; Eguchi Y; Hisanaga J; Nitawaki T; Iio M; Sekido Y; Nakano A; Sakagami T
Thorac Cancer; 2019 Dec; 10(12):2259-2266. PubMed ID: 31679185
[TBL] [Abstract][Full Text] [Related]
13. Effectiveness and safety of immune checkpoint inhibitors: A retrospective study in Taiwan.
Hsu JC; Lin JY; Hsu MY; Lin PC
PLoS One; 2018; 13(8):e0202725. PubMed ID: 30142174
[TBL] [Abstract][Full Text] [Related]
14. Looking for the best immune-checkpoint inhibitor in pre-treated NSCLC patients: An indirect comparison between nivolumab, pembrolizumab and atezolizumab.
Passiglia F; Galvano A; Rizzo S; Incorvaia L; Listì A; Bazan V; Russo A
Int J Cancer; 2018 Mar; 142(6):1277-1284. PubMed ID: 29080213
[TBL] [Abstract][Full Text] [Related]
15. Pembrolizumab for advanced nonsmall cell lung cancer: Efficacy and safety in everyday clinical practice.
Ksienski D; Wai ES; Croteau N; Freeman AT; Chan A; Fiorino L; Brooks EG; Poonja Z; Fenton D; Geller G; Irons S; Lesperance M
Lung Cancer; 2019 Jul; 133():110-116. PubMed ID: 31200816
[TBL] [Abstract][Full Text] [Related]
16. Fast progression in non-small cell lung cancer: results from the randomized phase III OAK study evaluating second-line atezolizumab versus docetaxel.
Gandara D; Reck M; Moro-Sibilot D; Mazieres J; Gadgeel S; Morris S; Cardona A; Mendus D; Ballinger M; Rittmeyer A; Peters S
J Immunother Cancer; 2021 Mar; 9(3):. PubMed ID: 33737340
[TBL] [Abstract][Full Text] [Related]
17. Evaluation of the Lung Immune Prognostic Index for Prediction of Survival and Response in Patients Treated With Atezolizumab for NSCLC: Pooled Analysis of Clinical Trials.
Sorich MJ; Rowland A; Karapetis CS; Hopkins AM
J Thorac Oncol; 2019 Aug; 14(8):1440-1446. PubMed ID: 30999110
[TBL] [Abstract][Full Text] [Related]
18. Atezolizumab in patients with advanced non-small cell lung cancer and history of asymptomatic, treated brain metastases: Exploratory analyses of the phase III OAK study.
Gadgeel SM; Lukas RV; Goldschmidt J; Conkling P; Park K; Cortinovis D; de Marinis F; Rittmeyer A; Patel JD; von Pawel J; O'Hear C; Lai C; Hu S; Ballinger M; Sandler A; Gandhi M; Fehrenbacher L
Lung Cancer; 2019 Feb; 128():105-112. PubMed ID: 30642441
[TBL] [Abstract][Full Text] [Related]
19. Efficacy of immune checkpoint inhibitor monotherapy for patients with massive non-small-cell lung cancer.
Hakozaki T; Hosomi Y; Kitadai R; Kitagawa S; Okuma Y
J Cancer Res Clin Oncol; 2020 Nov; 146(11):2957-2966. PubMed ID: 32462297
[TBL] [Abstract][Full Text] [Related]
20. Immunotherapy revolutionises non-small-cell lung cancer therapy: Results, perspectives and new challenges.
Giroux Leprieur E; Dumenil C; Julie C; Giraud V; Dumoulin J; Labrune S; Chinet T
Eur J Cancer; 2017 Jun; 78():16-23. PubMed ID: 28407528
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]